ArticleCureus2025
IgG4-Related Disease: A Case Series Highlighting Diverse Clinical Manifestations and Treatment Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgG4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory condition characterized by tumor-like swelling of affected organs, lymphoplasmacytic infiltration enriched with IgG4-positive plasma cells, and variable degrees of fibrosis. We present three cases of IgG4-RD with diverse clinical presentations, highlighting the diagnostic challenges and management approaches. Our cases include a 45-year-old female with lacrimal and salivary gland involvement mimicking Sjögren's syndrome, a 77-year-old male with pancreatic mass, mesenteric vasculitis, and intra-abdominal lymphadenopathy initially suspected as pancreatic cancer, and a 75-year-old male with diffuse lymphadenopathy, initially thought to be lymphoma. All patients were successfully treated with rituximab with good clinical and radiological responses, emphasizing the importance of considering IgG4-RD in the differential diagnosis of conditions with multisystem involvement and atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.